Stopped: Sponsor Decision
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer which has spread to other parts of the body. This study is seeking participants who: * have lung cancer that has reached at least the brain. * have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work. * have not received any treatment before. All participants in this study will receive dacomitnib 1 time a day. Dacomitinib is a tablet that is taken by mouth at home. They can continue to take dacomitnib until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
The real-world intracranial overall response rate (rwICORR) at Month 3
Timeframe: 3 months from first dose of dcomitnib
The real-world intracranial overall response rate (rwICORR) at Month 6
Timeframe: 6 months from first dose of dacomitnib
The real-world intracranial overall response rate (rwICORR) at Month 12
Timeframe: 12 months from first dose of dacomitinib
The real-world intracranial clinical benefit rate (rwICBR) at Month 3
Timeframe: 3 months from first dose of dacomitinib
The real-world intracranial clinical benefit rate (rwICBR) at Month 6
Timeframe: 6 months from first dose of dacomitinib
The real-world intracranial clinical benefit rate (rwICBR) at Month 12
Timeframe: 12 months from first dose of dacomitinib
The real-world intracranial time to progression (rwICTTP)
Timeframe: 30 months from first dose of dacomitinib
The real-world systemic overall response rate (rwORR) at Month 3
Timeframe: 3 months from first dose of dacomitinib
The real-world systemic overall response rate (rwORR) at Month 6.
Timeframe: 6 months from first dose of dacomitinib
The real-world systemic overall response rate (rwORR) at Month 12.
Timeframe: 12 months from first dose of dacomitinib
The real-world progression-free survival (rwPFS) during 12 months from index date
Timeframe: 12 months from index date
The real-world overall survival (rwOS) during 12 months from index date
Timeframe: 12 months from index date
The real-world overall survival (rwOS) during 24 months from index date
Timeframe: 24 months from index date